

Evaluation of Feasibility of TrueBeam HyperSight Imaging for Adaptive Treatment Planning for Breast Patients

Purity Bundi, MS, Dominic DiCostanzo, PhD, Robyn Handschuh, MS, Eric Cochran, PhD, Samantha Morelli, MS, Sachin Jhawar, MD, Sasha Beyer, PhD, Nilendu Gupta, PhD, Sujith Baliga, MD, Ashley Cetnar, PhD
The Ohio State University Wexner Medical Center.

ABSTRACT

Purpose: HyperSight CBCT (HS-CBCT) incorporates advanced iterative reconstruction algorithms (iCBCT and iCBCT-MAR), which may improve image quality and enable CBCT-based dose calculations. This study evaluated the dosimetric accuracy of HS-CBCT compared with CT simulation images in breast cancer patients.

Methods: Ten breast cancer patients from a prospective clinical trial (NCT06681233) were included. HS-CBCT images were acquired using two imaging protocols and reconstructed using standard and advanced algorithms. Treatment plans and structures from CT simulation were transferred to HS-CBCT datasets, and DVH metrics for target volumes and organs at risk were compared

Results: Compared with CT-sim HS-CBCT demonstrated small deviations in mean heart dose and PTV D95.

Conclusion: HS-CBCT demonstrated feasible dose calculation accuracy for breast radiotherapy. These findings support the potential use of HS-CBCT in adaptive radiotherapy workflows

DISCLOSURE

This research included a prospective imaging clinical trial (NCT06681233) supported by Varian Medical Systems/Siemens Healthineers

CONTACT


Purity Kemunto Bundi
The Ohio State University Wexner Medical Center
460 W 10th Ave, Columbus, OH
bund22@osumc.edu
225-433-6951

INTRODUCTION

- CT Simulation (**CT-sim**) provides accurate HU values for treatment planning, whereas **standard CBCT** has limited dosimetric utility because of scatter related to its cone-beam geometry¹.
- Anatomical changes during breast radiotherapy may require replanning, and **HS-CBCT** with **iCBCT** and **iCBCT-MAR** may facilitate adaptive radiotherapy by improving image quality and HU accuracy for dose calculation.
- This study evaluates the dose calculation accuracy of **HS-CBCT** by comparing the dosimetric difference with **CT-sim** for breast cancer patients.

METHODS AND MATERIALS


- Ten breast patients were evaluated as part of a larger prospective clinical trial comparing **CT-sim** images with **standard CBCT (SCBCT)** and **HS-CBCT** images.



- Four patients were treated using breath-hold techniques, four were treated in the prone position, and two patients had breast expanders.
- HS-CBCT images were acquired using two different 125 kV protocols with 1.2 mAs for **HS-A** or 0.3 mAs for **HS-B**. Both protocols were used to evaluate the effect of different acquisition protocols on CBCT- based dose calculations.

- **HS-CBCT** were reconstructed using standard FDK, iCBCT, or **iCBCT-MAR** algorithms.




- Data analysis process map:



RESULTS

Metric	$D_{95}(\%)$	$Heart D_{mean}(cGy)$	$Lung D_{mean}(cGy)$
Standard CBCT	-0.57 ± 1.29 (p=0.54)	3.55 ± 9.17 (p=0.32)	-30.65 ± 46.56 (p=0.07)
HS-A	2.06 ± 4.75 (p=0.11)	-0.12 ± 4.76 (p=0.68)	-15.68 ± 19.91 (p = 0.03)
HS-B	2.82 ± 6.01 (p=0.10)	1.37 ± 5.89 (p=0.74)	-13.89 ± 18.59 (p = 0.04)


Table 1: Dosimetric differences between CT-sim and CBCT images, calculated as $(D_{CTsim} - D_{CBCT})$. Values are reported as average $\pm$ standard deviation with p-values from two-tailed paired t-tests for PTV D_{95} , mean lung and heart doses. HS-A and HS-B: HyperSight CBCT acquired using protocol A and B respectively.



- Both HS protocols provided more accurate dosimetric representations D_{mean} of Heart with greatest improvements using the HS-CBCT A protocol
- Both HS protocols provided more accurate dosimetric representation D_{mean} of Lung with greatest improvements using the HS-CBCT B protocol.
- Paired t-test showed no significant statistical differences in PTV D_{95} or mean heart dose (p > 0.05). Mean lung dose showed statistical difference (p < 0.05) for HS-A and HS-B compared to the original CT used for treatment planning.

DISCUSSION

- **iCBCT-MAR** improved HU accuracy and reduced image artifacts, which may have contributed to the observed **reduction in dose calculation discrepancies** for patients with metal implants
- The dosimetric difference in **PTV D_{95}** across **HS-CBCT** may be due to **differences in external body contour**.
- Differences in body contour between CT-sim and HS-CBCT may have **altered depth of dose calculation** and contributed to **dose variability**².



CONCLUSIONS

- **iCBCT-MAR** resulting in more accurate dose calculations for OARs evaluated than standard CBCT while retaining accuracy for target volume evaluation.
- **HS-CBCT** demonstrated feasibility for dose calculation in our small cohort of breast patients for this evaluation.
- The ability to perform dose calculations directly on HS-CBCT images may facilitate **adaptive radiotherapy workflows**.

REFERENCES

1. Gregg, K. W., Arsenault, T., Rezaei, A., Kashani, R., Henke, L., & Price, A. T. (2025). Hounsfield Unit characterization and dose calculation on a C-arm linac with novel on-board cone-beam computed tomography feature and advanced reconstruction algorithms. *Journal of Applied Clinical Medical Physics*, 26(8), e70145–e70145.
2. Kenneth W. Gregg, Theodore Arsenault, Sagar Regmi, Kyle O'Carroll, Beatriz Guevara, Meiyang Xing, Runyon Woods, Atefeh Rezaei, Rojano Kashani, Lauren Henke, Alex Price. First evaluation of in-patient dose calculation accuracy on a C-arm Linear Accelerator with advanced Cone-Beam computed tomography (CBCT) imaging. *Physics and Imaging in Radiation Oncology*, Volume 39, 2026, 100991, ISSN 2405-6316.